Sionna Therapeutics, Inc. (NASDAQ:SION) Receives Average Recommendation of “Moderate Buy” from Brokerages

Sionna Therapeutics, Inc. (NASDAQ:SION) has been given a consensus rating of “Moderate Buy” by the eleven brokerages that are currently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, six have issued a buy rating and three have given a strong buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $53.00.

Several equities analysts have issued reports on SION shares. JonesTrading boosted their price objective on shares of Sionna Therapeutics from $52.00 to $63.00 and gave the company a “buy” rating in a research note on Tuesday, April 28th. Citizens Jmp began coverage on shares of Sionna Therapeutics in a research note on Tuesday, February 24th. They set a “market outperform” rating and a $63.00 price target on the stock. UBS Group reaffirmed a “buy” rating on shares of Sionna Therapeutics in a research note on Monday, March 2nd. Wedbush began coverage on shares of Sionna Therapeutics in a research note on Tuesday, May 5th. They set an “outperform” rating and a $53.00 price target on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sionna Therapeutics in a research note on Friday, May 8th.

Insiders Place Their Bets

In other news, Director Orbimed Advisors Llc sold 235,863 shares of the company’s stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $44.64, for a total transaction of $10,528,924.32. Following the transaction, the director directly owned 3,247,025 shares of the company’s stock, valued at $144,947,196. This represents a 6.77% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter A. Thompson sold 235,863 shares of the company’s stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $44.64, for a total transaction of $10,528,924.32. Following the transaction, the director directly owned 3,247,025 shares in the company, valued at approximately $144,947,196. This trade represents a 6.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 1,717,760 shares of company stock worth $77,562,902. Corporate insiders own 3.90% of the company’s stock.

Institutional Investors Weigh In On Sionna Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Russell Investments Group Ltd. purchased a new stake in shares of Sionna Therapeutics in the 3rd quarter worth about $30,000. BNP Paribas Financial Markets purchased a new stake in shares of Sionna Therapeutics in the 2nd quarter worth about $31,000. GF Fund Management CO. LTD. purchased a new stake in shares of Sionna Therapeutics in the 4th quarter worth about $36,000. Balyasny Asset Management L.P. purchased a new stake in shares of Sionna Therapeutics in the 4th quarter worth about $58,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Sionna Therapeutics in the 4th quarter worth about $89,000.

Sionna Therapeutics Stock Performance

Shares of SION opened at $40.22 on Monday. The stock has a market capitalization of $1.82 billion, a P/E ratio of -20.84 and a beta of 1.35. The company’s fifty day moving average is $39.40 and its two-hundred day moving average is $39.55. Sionna Therapeutics has a 1 year low of $12.42 and a 1 year high of $48.44.

Sionna Therapeutics (NASDAQ:SION) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by ($0.08). Sell-side analysts predict that Sionna Therapeutics will post -2.53 EPS for the current year.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.